Navigation Links
X-BODY BioSciences Awarded Grant for Therapeutic Discovery Project Targeting Metastatic Tumor Stem Cells
Date:11/1/2010

WALTHAM, Mass., Nov. 1, 2010 /PRNewswire/ -- X-BODY BioSciences, a developer of human monoclonal antibody therapeutics, today announced it has been awarded a research grant under the Patient Protection and Affordable Care Act of 2010 for its human monoclonal antibody therapeutic project targeting metastatic tumor stem cells.  The grant was awarded by the US Department of the Treasury and reviewed by scientists at the Department of Health and Human Services.  This grant provides X-BODY with the maximum allowable 50% reimbursement of X-BODY's qualified investment of ~$500,000 in this project.

X-BODY's therapeutic candidates target a kinase signaling pathway that is believed to mediate metastasis (invasion and spreading) of cancer tumor initiating stem cells. There is no selective inhibitor of this targeted pathway on the market. Targeting tumor-initiating cells via this pathway alone or with combination therapy may prevent metastasis in the treatment of non-small cell lung cancer and other solid tumors.  Non-small cell lung cancer is a very common cancer with an 11-14% five-year survival rate and causes ~1.4 million yearly deaths globally.

X-BODY's pre-clinical candidates were discovered using X-BODY's proprietary platform, based on innovative screening technology allowing for rapid generation of human antibody therapeutics of high affinity and selectivity, via deep sequence interrogation of fully human DNA libraries.    

About X-BODY BioSciences.

X-BODY BioSciences was founded in 2008 by Richard Wagner, Ph.D., Gordon Binder, and Brant Binder, MBA.   Dr. Wagner previously co-developed the fibronectin domain antibody-mimetic platform at Phylos, later acquired by Bristol Myers Squibb, and the DirectSelect small molecule library screening system at Praecis Pharmaceuticals, acquired by GlaxoSmithKline in 2007.  Mr. Gordon Binder is the former CEO and Chairman of Amgen and member of the boards of the American Enterprise Institute, the Massachusetts Institute of Technology and the California Institute of Technology. Mr. Brant Binder is co-founder, COO and CFO of SRU Biosystems.  X-BODY's platform enables rapid discovery of human antibody therapeutics by interrogation of extraordinarily diverse fully human libraries.  X-BODY's versatile selection system employs Next Generation sequencing to analyze thousands of hits in order to rapidly obtain high quality leads. X-BODY has employed the platform internally to identify high-affinity therapeutic candidates that target metastasis (invasion and spreading) of cancer stem cells.

Further information regarding X-BODY BioSciences can be obtained at:

WEB: www.x-bodybiosciences.com  


'/>"/>
SOURCE X-BODY BioSciences
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
2. Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
3. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
4. Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast
5. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
6. Cell Biosciences to Acquire Convergent Bioscience
7. YM Biosciences To Present Poster On CYT387 At The European School Of Haematology International Conference
8. YM BioSciences licensee Pulmokine awarded NIH funding to develop small molecule drugs for pulmonary hypertension
9. YM BioSciences reports fiscal year end 2010 operational and financial results
10. Regado Biosciences to Present at the UBS Global Life Sciences Conference on September 22, 2010 in New York City
11. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... ... addition of Tom Perkins as European director. Operating from Pennside’s Zurich headquarters, Pennside ... , Perkins joins Pennside after more than a decade with leading market ...
(Date:2/22/2017)... N.C., Feb. 22, 2017  United Therapeutics Corporation (NASDAQ: ... results for the fourth quarter and year ended ... results reflect continued growth as net revenues reached ... Martine Rothblatt, Ph.D., United Therapeutics, Chairman and Chief ... to develop and advance our growing product pipeline, ...
(Date:2/21/2017)... Feb. 21, 2017 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the ... results for the three months ended December 31, 2016. ... life sciences and diagnostics company that develops and commercializes proprietary ... ... build on the commercial milestones achieved in fiscal 2016," said ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... Liquid Biopsy System , a fully automated benchtop system for collecting intact circulating ... is being launched at the Molecular Medicine Tri Conference (Tri-Con) Annual Meeting 2017 ...
Breaking Biology Technology:
(Date:2/1/2017)... BOSTON, Massachusetts , February 1, 2017 ... and events on emerging technology, announces the availability of a new ... Continue Reading ... ... systems in industrial and collaborative robots. Source: IDTechEx Report "Sensors for ...
(Date:1/30/2017)... --  Invitae Corporation (NYSE: NVTA ), ... announced that it will report its fourth quarter and ... Monday, February 13, 2017, and Invitae,s management team will ... Eastern / 1:45 p.m. Pacific. During ... results, guidance, and recent developments and will spend the ...
(Date:1/26/2017)... DENVER , Jan. 26, 2017  Acuity ... Trends for Biometrics and Digital Identity".  Acuity characterizes ... digital identity when increased adoption reflects a new ... "Biometrics and digital identity are ... says Maxine Most , Principal of Acuity ...
Breaking Biology News(10 mins):